Kornimate/medical-research-clean huggingface dataset:
high dose oral versus intramuscular vitamin d3 supplementation in multiple sclerosis patients

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: this study aimed to evaluate oral and injectable routes in treatment of hypovitaminosis d in multiple sclerosis (ms) patients. the investigators aimed to assess the efficacy of each method, using the same mega dose of 600 000 iu d3, in achieving normal serum 25(oh)d level, the durability of the response, the practicality and the possible toxicity.

ultraviolet sunlight is too low to produce adequate amounts of vitamin d3, and vitamin d insufficiency lasting 4 to 6 months of the year at latitudes of ≥42° is common in individuals with low vitamin d intake. vitamin d has strong immunoregulatory effects, and vitamin d supplementation prevents experimental autoimmune encephalomyelitis (eae), an autoimmune disease in animals that is used as a model of ms. recently, emerging data from epidemiologic studies suggest that vitamin d may play an important role in the progression of the development of ms. a longitudinal study in pediatric ms showed a 34% lower risk of relapse for every 10 ng/ml higher 25-hydroxyvitamin d level. a similar magnitude of reduced relapse risk was later reported in an adult ms cohort. higher vitamin d levels have also been shown to be associated with less subsequent inflammatory ms activity on brain magnetic resonance imaging (mri). finally, studies have demonstrated that patients have lower vitamin d levels during ms relapses.

Eligibility criteria:
inclusion criteria: * with serum 25(oh)d3 concentration ≤ 20 ng/ml exclusion criteria: * hypercalcaemia, primary hyperparathyroidism, paget disease, thyrotoxicosis, pregnancy, active malignancy, hypercalciuria, history of liver disease, renal insufficiency, clinically apparent malabsorption syndrome, using drugs containing vitamin d products, calcium, estrogen and drugs known to affect vitamin d metabolism (anticonvulsants, glucocorticoids) or receiving any form of supplements containing vitamin d during last 6 months. * participants with serum 25(oh)d concentration≥ 20 ng/ml
treatment with indinavir and chemotherapy for advanced classical kaposi's sarcoma

Conditions: Kaposi's Sarcoma

Summary: the purpose of this study is to determine the clinical response to daily indinavir oral administration in association with a conventional chemotherapy based on cycles of systemic vinblastine +/- bleomycin in patients affected by advanced classical (non hiv-associated) kaposi's sarcoma

it has been recently demonstrated that hiv protease inhibitors (hiv-pi) exert direct anti-angiogenic and anti-tumor actions by blocking endothelial and tumor cell invasion and matrix metalloprotease (mmp) activity. based on this data, we have started a phase ii trial for the treatment of hiv-negative patients with cks with the hiv-pi indinavir. indinavir was well tolerated and induced ks regression/improvement in early-stage disease, and prolonged stabilization in late-stage ks. response required high plasma drug concentrations indicating a "therapeutic" drug threshold, and was associated with a decrease of circulating endothelial cells (cec), basic fibroblast growth factor and mmp2 plasma levels. however, large, confluent tumor masses were generally not responsive (monini et al, aids 2009). thus, advanced ks may benefit at best by treatment with ind upon tumor debulking by conventional chemotherapy.

Eligibility criteria:
inclusion criteria: * documented diagnosis of ks * negative hiv elisa test * being classified as stage iii or iv * age ≥18 years * having interrupted any other anti-ks therapy since at least 2 weeks * being informed about the nature of the study and having signed the informed consent exclusion criteria: * inability to give informed consent * presence of other concomitant diseases, neoplasia (excluding cutaneous tumors with limited extension and without diagnosis of melanoma) or any other life-threatening clinical condition that would compromise its compliance to the protocol * concomitant treatments (within 2 weeks prior to the study) with systemic immunomodulatory agents (i.e. glucocorticoids used as immunosuppressive agents, interferons) or chemotherapy * pregnancy * monolateral nephropathy or history of nephrolithiasis during the last 5 years * any clinically relevant and persistent alteration of laboratory values observed during screening

Keywords: classical kaposi's sarcoma chemotherapy indinavir hiv protease inhibitor advanced classical (non hiv-associated) kaposi's sarcoma
effect of single-versus double-limb cycling exercise on blood flow in patients with peripheral artery disease

Conditions: Peripheral Arterial Disease

Summary: this study will be conducted to investigate the effect of single limb cycling exercise and the effect of double limb cycling exercise on blood flow in patients with peripheral artery disease and compare between both effects.

global populations are undergoing a major epidemiological transition in which the burden of atherosclerotic cardiovascular diseases is shifting rapidly from high-income to low-income and middle-income countries (lmics). peripheral artery disease (pad) is no exception, so that greater focus is now required on the prevention and management of this disease in less-advantaged countries (gerry et al., 2017) pad prevalence and incidence are both sharply age-related, rising \>10% among patients in their 60s and 70s. with the aging of the global population, it seems likely that pad will be increasingly common in the future. prevalence seems to be higher among men than women for more severe or symptomatic disease (michael et al., 2015). pad causes leg pain, impaired health-related quality of life, immobility, tissue loss and a high risk of major adverse events, including myocardial infarction, stroke, revascularization, amputation and death. the drug cilostazol, exercise therapy and revascularization are the current treatment options for the limb symptoms of pad, but each has limitations (jonathan et al., 2022) few studies conducted the importance of active and passive movements and aerobic exercises for cardiovascular especially peripheral artery disease patients as mentioned previously, thus the aim of this study is to conduct single limb cycling exercise and double limbs cycling exercise to pad patient to determine the effect of cycling on blood flow velocity and which is more effective and leads to more benefits compared to the control group.

Eligibility criteria:
inclusion criteria: * 1. mild to moderate pad ( abi ranges from less than 0.90 to 0.50) 2. intermittent claudication / typical claudication 3. their age will be ranged from 50_60 years old. 4. quitting smoking for more than 3 months 5. body mass index (bmi) from 25.0 to 29.9kg/m2. exclusion criteria: * 1. patients with uncontrolled pulmonary disease. 2. patients with vascular severe complication as critical limb ischemia(abi less than 0.5) 3. patients with unstable angina, uncontrolled cardiac arrhythmia, decompensated heart failure. 5. patients with severe musculoskeletal problems (e.g., severe knee osteoarthritis or post knee replacement surgeries). 6. any patients who missed more than two weeks of the program or want to terminate the program.
a efficacy and safety study of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer

Conditions: Advanced Non-squamous Cell Non-small Cell Lung Cancer

Summary: this is a randomized, double-blind, multicenter phase iii clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * 1. local advanced (stage iiib / ⅲc), metastatic or recurrent (stage iv) non-squamous cell non-small cell lung cancer, has at least one measurable lesion. 2. egfr, alk, and ros1 test results are negative. 3. eastern cooperative oncology group (ecog) performance status of 0 or 1, life expectancy≥ 12 weeks. 4. has not received systemic anti-tumor treatment for advanced disease. 5.adequate organ system function. 6. male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ; no pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization. 7. understood and signed an informed consent form. exclusion criteria: * 1.other histopathological types of non-small cell lung cancer. 2.has received vegf pathway targeted therapy including anlotinib and bevacizumab. 3. has multiple factors affecting oral medication. 4. has symptomatic brain metastases. 5. has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. 6. has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1. 7. has any severe and / or uncontrolled diseases. 8. has any bleeding symptoms or treated with anticoagulants or vitamin k antagonists. 9.has received surgery, or unhealed wounds within 4 weeks before the first administration. 10. has hemoptysis within 28 days before randomization. 11. imaging (ct or mri) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear. 12. has arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident including transient ischemic attack, deep vein thrombosis and pulmonary embolism. 13. has psychotropic substances abuse or a mental disorder. 14. have a history of immunodeficiency. 15. has received allogeneic organ transplantation, hematopoietic stem cell transplantation or bone marrow transplantation. 16. has other malignancy. 17.has participated in other anticancer drug clinical trials within 4 weeks. 18.according to the judgement of the researchers, there are other factors that may lead to the termination of the study.
neuromuscular ultrasonography assessment of optic nerve in systemic lupus eryhematosus

Conditions: Optic Neuropathy

Summary: assessing the role of neuromuscular ultrasound in optic nerve involvement in systemic lupus patients.

evaluating the role of neuromuscular ultrasound in optic nerve involvement in systemic lupus patients.by measuring the diameter of optic nerve at certain site and comparing it to healthy subjects measurements and to asses nmus ability to detect optic neuropathy in lupus patients in comparison to conventional techniques including opthalmologist evaluation and visual evoked potential

Eligibility criteria:
inclusion criteria: * adult * group of sle patients, who fulfilled systemic lupus international collaborating clinics classification criteria for sle (slicc) with or without symptoms of optic neuropathy * another group of apparently healthy subjects with no. history of chronic conditions exclusion criteria: * any patient with optic neuritis due to causes other than lupus was excluded from the study: ex. * post traumatic neuropathy * purely degenerative neuropathy * diabetic neuropathy * toxic neuropathy * neuropathies related to infections * drug induced neuropathy e.g: quinine and some antibiotics, ethambutol * infections e.g. measles, mumps, lyme disease, etc. * other autoimmune diseases like sarcoidosis, b.d * tumor causing inc. intracranial tension.
preparing for eating disorders treatment through compassionate letter-writing

Conditions: Eating Disorders; Anorexia Nervosa; Bulimia Nervosa; Binge-Eating Disorder; Compassion

Summary: compassion-focused therapy (cft) seeks to lower shame and help people develop compassion for personal distress and shortcomings. there is increasing evidence to support the benefits of incorporating cft-based interventions into the treatment of eating disorders (eds). building on the investigators' prior research, this study will examine the effects of a two-week cft-based self-compassion letter-writing intervention on patients with eating disorders. participants will be recruited from the wait-list of patients scheduled to begin treatment at the outpatient st. joseph's healthcare hamilton eating disorders program, and will be randomly assigned to the two-week letter-writing intervention or to a control group. results will inform the integration of new empirically-derived interventions into ed treatments to improve the currently dismal rates of ed recovery.

the study consists of two phases. in phase one, participants will be randomly assigned to a two-week daily letter-writing intervention condition or a two-week control condition; phase one will occur two to four weeks prior to the start date of group ed treatment. participants will complete a brief set of online questionnaires pre-, mid-, and post- two-week condition (i.e. baseline, after one week, and after two weeks). following these two weeks of intervention/control condition, all participants will complete a 25-week group treatment program as scheduled by the eating disorders program. for phase two of the study, participants will be asked to complete questionnaires after 5 weeks, after 11 weeks, and post-group treatment. data that is routinely collected as part of patients' clinical care pre- and post-treatment (i.e. on the first day and last week of group treatment) will also be collected.

Eligibility criteria:
inclusion criteria: 1. dsm-5 diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder 2. eligible to start group eating disorders treatment at st. joseph's eating disorder program 3. 17 years of age or older exclusion criteria: none
vitamin d and physical performance before and after intervention and birth outcome in pregnant somali and swedish women

Conditions: Muscle Weakness; Vitamin D Deficiency

Summary: somali migrant women, often in veiled clothing, living in a town in mid sweden on the 60:th parallel were observed to be weak and to have a waddling gate. study 1 was carried out in the setting of an antenatal clinic administered from a primary care center in borlänge, a swedish middle-sized industrial town at the 60:th parallel in sweden. the investigators chose an initial study period in late spring to reflect the effects of the dark season with little ultraviolet b radiation that affects vitamin d production. study 1 was carried out in a short period of time. the recruitment was performed in a retrospective design in order to neglect the seasonal effects of ultraviolet b radiation. study 1 was carried out in year 2010. it was a cross sectional baseline study of blood levels of vitamin d measured as 25-hydroxyvitamin d (25-ohd) and physical performance in 123 pregnant and new mothers from somalia (n=52) and sweden (n=71). study 2: examines the results on muscular performance, i.e. grip strength and squatting ability, from intervention with advice and prescription of vitamin d3 and calcium for 10 months, in all the women from study 1 with 25-ohd levels \<50 nmol/l or 50 nmol/l of 25-ohd. study 3: the recruitment to study 1 also serves as recruitment for a cohort study on delivery outcome in birth protocols starting 2016. study 4: the aim is to study the emic perspective and lifestyle related to vitamin d and strength in the group of somali women by focus interviews among the somali women from above. a possible fifth study will explore correlations between 25-ohd and pain distribution and pain parameters.


Eligibility criteria:
inclusion criteria: * pregnant or new mother from sweden or somalia living in borlänge and registered the antenatal clinic in borlänge maximally 21 months prior to study start. exclusion criteria: * severe metabolic, medical or mental disease (ex. deranged type i diabetes or psychosis).
vaccination against pertussis, tetanus and diphtheria in patients suffering from rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: pertussis is an acute respiratory infection caused by bordetella pertussis. rates of recent b. pertussis infection between 8%--26% have been reported among adults with cough illness of at least 5 days duration who sought medical care. the cdc recommends vaccinating patients aged 15 to 64 years old, once in 10 years. although acellular vaccines such as boostrix have been evaluated in healthy population, the safety and efficacy of this vaccine in patients suffering from rheumatic diseases have not been established. study population : 50 rheumatoid arthritis (ra) patients and 5 healthy controls evaluation : the evaluation will be performed on week 0 and 4-6 weeks later. in terms of safety, the patients will be evaluated according to the disease activity index (das). blood will be drawn at each visit at tested for humoral response to tetanus and pertussis.


Eligibility criteria:
inclusion criteria: * patients suffering from ra * aged 18 to 64 years old exclusion criteria: * active disease requiring a change in drug regimen * known allergy to vaccine

Keywords: rheumatoid pertussis tetanus
cardiac rehabilitation in cardiomyopathies

Conditions: Cardiomyopathies

Summary: this quantitative study aimed to evaluate the respiratory muscle strength, pulmonary function, cardiovascular function, and impact on quality of life in patients after cardiac rehabilitation associated with the diaphragmatic muscle training.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of cardiomyopathies in functional class iii or iv (new york heart association) * aged over 18 years * body mass index below 30 kg/m2 exclusion criteria: * confused and depressed patients * cardiac instability and worsening dyspnea after initiation of treatment

Keywords: rehabilitation dyspnea strength
to improve depressive symptoms using a web-app

Conditions: Depression

Summary: this study is being done to answer a question on whether a web app-based lifestyle physical activity promotion program is effective in improving depressive symptom experience of midlife korean american women (wpapp-k).

this study is being done to answer a question on whether a web app-based lifestyle physical activity promotion program is effective in improving depressive symptom experience of midlife korean american women (wpapp-k). korean american midlife women tend to suffer from depressive symptoms due to their menopausal transition, cultural background, age, and gender. the wpapp-k program that the investigators are testing is designed to help korean american midlife women by providing information and coaching/support to increase lifestyle physical activity and subsequently improve their depressive symptom experience during the menopausal transition. the research team wants to know if the program improves depressive symptom experience of korean american midlife women as designed.

Eligibility criteria:
inclusion criteria: * self-reported midlife korean-american women * aged 40 to 60 years * whose parents and grandparents are of korean descent; * who can read and write english or korean; * who currently reside in the united states; * who are sedentary (without any disabilities preventing physical activity); * who are online through computers or mobile devices; * have experienced depressive symptoms during the past two weeks (1 to 10 on the patient health questionnaire \[phq-9\],which is equivalent to the cut-point of minimal to moderate depression. exclusion criteria: * major signs or symptoms suggestive of pulmonary or cvd * history of a myocardial infarction, stroke, or type i diabetes mellitus * blood pressure higher than 160/100 mm hg * use of beta-blockers, diltiazem, or verapamil

Keywords: depression korean american women
opal study: a study of avastin (bevacizumab) in combination with folfoxiri in patients with previously untreated metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this single arm study will assess progression-free survival, feasibility of use and safety of avastin in combination with 5-fu/fa, oxaliplatin and irinotecan (folfoxiri) as first line treatment in patients with metastatic colorectal cancer. patients will receive up to 12 bi-weekly cycles of avastin (5mg/kg iv) in combination with this standard neoadjuvant chemotherapy regimen followed by up to 40 bi-weekly cycles with avastin plus 5-fu/fa. the anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-70 years of age; * metastatic colorectal cancer scheduled for standard first line chemotherapy; * at least 1 measurable lesion; * ecog performance score of 0 or 1. exclusion criteria: * prior chemotherapy for metastatic colorectal cancer; * prior (neo)adjuvant chemotherapy/radiotherapy of a non-metastatic malignancy completed within 6 months prior to study entry; * concomitant malignancies other crc; * history or evidence of cns disease unrelated to cancer.
transcranial magnetic stimulation and cognitive stimulation in mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this study evaluates the effect of 5hertz (hz) repetitive transcranial magnetic stimulation (rtms) on left dorsolateral prefrontal cortex enhancing cognitive stimulation in mild cognitive impairment.

mild cognitive impairment (mci) is defined as an intermediate state between normal aging and an early stage of neurodegenerative diseases. it is estimated that exist 24.3 million people worldwide with neurocognitive disorders. cognitive stimulation (cs) is defined as the set of techniques and strategies that optimize the effectiveness in various functions of different cognitive abilities throughout its use in rehabilitation on mci. transcranial magnetic stimulation (rtms) is a safe neuromodulation technique that modifies brain electrical activity through electromagnetic fields. there is evidence of the relationship between cs and rtms for the improvement in mci levels and cognitive functions; it´s important to deepen the knowledge of the therapeutic potential of both techniques combined on mci

Eligibility criteria:
inclusion criteria: * subjects of both genders. * subjects from 60 to 85 years old. * meet diagnostic and statistical manual, 5th edition (dsm-5) diagnostic criteria for mild cognitive impairment. * patients must provide their oral and written informed consent. exclusion criteria: * subjects with history of traumatic brain injury with loss of consciousness. * subjects with intracranial metallic objects or metal plates in the skull. * subjects diagnosed with uncontrolled chronic (for example: hypertension, diabetes) or neurological diseases. * comorbidity with other mental illness. * presence of psychotic symptoms, bipolar disorder and substance abuse. * alterations in the electroencephalogram (epileptiform activity).

Keywords: mild cognitive impairment
mad in cancer patients: safety of bms-582664 in patients with advanced or metastatic solid tumors

Conditions: Tumors; Neoplasm Metastasis

Summary: this is a phase i dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of bms-582664 in patients with advanced or metastatic solid tumors.


Eligibility criteria:
inclusion criteria: * diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors * no tumor spread to the brain * feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.) * available tumor tissue sample from prior surgery * 4-6 weeks since prior therapy and recovered from prior therapy * men and women, ages 18 and above * women must not be pregnant or breastfeeding * diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer * measurable disease on scans (at least one)

Keywords: advanced metastatic or solid tumors